

IN THE CLAIMS:

Please cancel claim 11.

Please amend the claims as follows.

7  
a  
HAVING  
"OPEN"  
CONSENSUS

-- 1 (amended). A substantially pure conopeptide or [pharaceutically] pharmaceutically acceptable salt thereof, said conopeptide having the general formula I: [Xaa<sub>1</sub>-Cys-Xaa<sub>2</sub>-Cys-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Cys-Cys-Xaa<sub>5</sub>-Cys-Xaa<sub>6</sub>-Cys-Xaa<sub>7</sub> (SEQ ID NO:1), wherein Xaa<sub>1</sub> is des-Xaa<sub>1</sub> or a peptide having 1-6 amino acids; Xaa<sub>2</sub> is a peptide having 5-6 amino acids; Xaa<sub>3</sub> is a peptide having 4 amino acids; Xaa<sub>4</sub> is Glu,  $\gamma$ -carboxyglutamic acid ( $\gamma$ -Glu) or Gln; Xaa<sub>5</sub> is a peptide having 3-4 amino acids; Xaa<sub>6</sub> is a peptide having 3-6 amino acids; and Xaa<sub>7</sub> is des-Xaa<sub>7</sub> or a peptide having 2-9 amino acids, with the proviso that when Xaa<sub>1</sub> is des-Xaa<sub>1</sub>, then Xaa<sub>5</sub> is not the tripeptide Ser-Asp-Asn] ~~Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Cys-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Cys-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>4</sub>-Cys-Cys-Xaa<sub>5</sub>-Xaa<sub>6</sub>-Xaa<sub>7</sub>-Xaa<sub>8</sub>-Cys-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Xaa<sub>3</sub>-Cys-Xaa<sub>9</sub>-Xaa<sub>9</sub>-Xaa<sub>10</sub>-Xaa<sub>10</sub>-Xaa<sub>10</sub>-Xaa<sub>10</sub>-Xaa<sub>10</sub>-Xaa<sub>10</sub>-Xaa<sub>10</sub>~~ (SEQ ID NO:1), wherein Xaa<sub>1</sub> is des-Xaa<sub>1</sub> or any amino acid; Xaa<sub>2</sub> is any amino acid; Xaa<sub>3</sub> is des-Xaa<sub>3</sub> or any amino acid; Xaa<sub>4</sub> is Glu,  $\gamma$ -Glu ( $\gamma$ -carboxyglutamic acid; also referred to as Gla) or Gln; Xaa<sub>5</sub> is any amino acid; Xaa<sub>6</sub> is any amino acid; Xaa<sub>7</sub> is any amino acid; Xaa<sub>8</sub> is des-Xaa<sub>8</sub> or any amino acid; Xaa<sub>9</sub> is des-Xaa<sub>9</sub> or any amino acid; and Xaa<sub>10</sub> is des-Xaa<sub>10</sub> or any amino acid, with the provisos that (a) when all Xaa<sub>10</sub> are des-Xaa<sub>10</sub>, then both Xaa<sub>9</sub> are des-Xaa<sub>9</sub> or any amino acid and (b) when all Xaa<sub>1</sub> are des-Xaa<sub>1</sub>, then ~~Xaa<sub>5</sub>-Xaa<sub>6</sub>-Xaa<sub>7</sub>-Xaa<sub>8</sub>~~ is not Ser-Asp-Asn. --

In claim 3, line 1, before "Xaa<sub>1</sub>", insert -- each --.

8  
a  
-- 4 (amended). The conopeptide of claim 1, wherein at least one Xaa<sub>1</sub> is any amino acid [a peptide having 1-6 amino acids]. --

-- 5 (amended). The conopeptide of claim 1, wherein [Xaa<sub>7</sub> is des-Xaa<sub>7</sub>] Xaa<sub>9</sub> is des-Xaa<sub>9</sub> and Xaa<sub>10</sub> is des-Xaa<sub>10</sub>. --

-- 6 (amended). The conopeptide of claim 1, wherein [Xaa<sub>7</sub> is a peptide having 2-9 amino acids] Xaa<sub>9</sub> is any amino acid. --

8  
a<sub>cont</sub>

-- 7 (amended). A substantially pure conopeptide or pharmaceutically acceptable salt thereof, said conopeptide having the general formula II: [Xaa<sub>1</sub>-Cys-Xaa<sub>2</sub>-Cys-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Cys-Cys-Xaa<sub>5</sub>-Xaa<sub>6</sub>-Cys-Xaa<sub>7</sub>-Cys-Xaa<sub>8</sub> (SEQ ID NO:2), wherein Xaa<sub>1</sub> is des-Xaa<sub>1</sub> or a peptide having 1-6 amino acids; Xaa<sub>2</sub> is a peptide having 5-6 amino acids; Xaa<sub>3</sub> is a peptide having 4 amino acids; Xaa<sub>4</sub> is Glu, γ-carboxyglutamic acid (γ-Glu) or Gln; Xaa<sub>5</sub> is Ser or Thr; Xaa<sub>6</sub> is a peptide having 2-3 amino acids; Xaa<sub>7</sub> is a peptide having 3-6 amino acids; and Xaa<sub>8</sub> is des-Xaa<sub>8</sub> or a peptide having 2-9 amino acids, with the proviso that when Xaa<sub>1</sub> is des-Xaa<sub>1</sub> and Xaa<sub>5</sub> is Ser, then Xaa<sub>6</sub> is not the dipeptide Asp-Asn] ~~Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Cys-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Cys-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>4</sub>-Cys-Cys-Xaa<sub>5</sub>-Xaa<sub>6</sub>-Xaa<sub>7</sub>-Xaa<sub>8</sub>-Cys-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Xaa<sub>3</sub>-Cys-Xaa<sub>9</sub>-Xaa<sub>9</sub>-Xaa<sub>10</sub>-Xaa<sub>10</sub>-Xaa<sub>10</sub>-Xaa<sub>10</sub>-Xaa<sub>10</sub>-Xaa<sub>10</sub>~~ (SEQ ID NO:2), wherein Xaa<sub>1</sub> is des-Xaa<sub>1</sub> or any amino acid; Xaa<sub>2</sub> is any amino acid; Xaa<sub>3</sub> is des-Xaa<sub>3</sub> or any amino acid; Xaa<sub>4</sub> is Glu, γ-Glu or Gln; Xaa<sub>5</sub> is Ser or Thr; Xaa<sub>6</sub> is any amino acid; Xaa<sub>7</sub> is any amino acid; Xaa<sub>8</sub> is des-Xaa<sub>8</sub> or any amino acid; Xaa<sub>9</sub> is des-Xaa<sub>9</sub> or any amino acid; and Xaa<sub>10</sub> is des-Xaa<sub>10</sub> or any amino acid, with the provisos that (a) when all Xaa<sub>10</sub> are des-Xaa<sub>10</sub>, then both Xaa<sub>9</sub> are des-Xaa<sub>9</sub> or any amino acid and (b) when all Xaa<sub>1</sub> are des-Xaa<sub>1</sub> and Xaa<sub>5</sub> is Ser, then Xaa<sub>6</sub>-Xaa<sub>7</sub>-Xaa<sub>8</sub> is not Asp-Asn. --

In claim 9, line 1, before "Xaa<sub>1</sub>", insert -- each --.

9  
a<sup>9</sup>

-- 10 (amended). The conopeptide of claim 7, wherein at least one Xaa<sub>1</sub> is any amino acid [a peptide having 1-6 amino acids]. --

-- 12 (amended). The conopeptide of claim 7, wherein [Xaa<sub>8</sub> is des-Xaa<sub>8</sub>] Xaa<sub>9</sub> is des-Xaa<sub>9</sub> and Xaa<sub>10</sub> is des-Xaa<sub>10</sub>. --

10  
a<sup>10</sup>

-- 13 (amended). The conopeptide of claim 7, wherein [Xaa<sub>8</sub> is a peptide having 2-9 amino acids] Xaa<sub>9</sub> is any amino acid. --

-- 14 (amended). A substantially pure conopeptide or pharmaceutically acceptable salt thereof, said conopeptide having the general formula III: [Xaa<sub>1</sub>-Cys-Xaa<sub>2</sub>-Cys-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Xaa<sub>5</sub>-Cys-Xaa<sub>6</sub> (SEQ ID NO:3), wherein Xaa<sub>1</sub> is a peptide having 1-6

a<sup>10</sup>  
cont

amino acids; Xaa<sub>2</sub> is a hexapeptide; Xaa<sub>3</sub> is a peptide having 4 amino acids; Xaa<sub>4</sub> is Glu or γ-carboxyglutamic acid (γ-Glu); Xaa<sub>5</sub> is a tripeptide; and Xaa<sub>6</sub> is a peptide having 7-9 amino acids] ~~Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Cys-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Cys-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>3</sub>-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Cys-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>~~ (SEQ ID NO:3) wherein Xaa<sub>1</sub> is any amino acid; Xaa<sub>2</sub> is des-Xaa<sub>2</sub> or any amino acid and Xaa<sub>3</sub> is Glu or γ-Glu. --

In claim 15, line 1, please change "Xaa<sub>4</sub>" to read -- Xaa<sub>3</sub> --.

a<sup>11</sup>

-- 16 (amended). A substantially pure conopeptide or pharmaceutically acceptable salt thereof, said conopeptide having the general formula IV: [Xaa<sub>1</sub>-Cys-Xaa<sub>2</sub>-Cys-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Xaa<sub>5</sub>-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Xaa<sub>6</sub>-Cys-Xaa<sub>7</sub> (SEQ ID NO:4), wherein Xaa<sub>1</sub> is a peptide having 1-6 amino acids; Xaa<sub>2</sub> is a hexapeptide; Xaa<sub>3</sub> is Ser or Thr; Xaa<sub>4</sub> is a tripeptide; Xaa<sub>5</sub> is Glu or γ-carboxyglutamic acid (γ-Glu); Xaa<sub>6</sub> is a tripeptide; and Xaa<sub>7</sub> is a peptide having 7-9 amino acids] ~~Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Cys-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Cys-Xaa<sub>3</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Cys-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>2</sub>~~ (SEQ ID NO:4), wherein Xaa<sub>1</sub> is any amino acid; Xaa<sub>2</sub> is des-Xaa<sub>2</sub> or any amino acid; Xaa<sub>3</sub> is Ser or Thr; and Xaa<sub>4</sub> is Glu or γ-Glu.

In claim 17, line 1, please change "Xaa<sub>5</sub>" to read -- Xaa<sub>4</sub> --.

a<sup>12</sup>

-- 18 (amended). A substantially pure conopeptide or pharmaceutically acceptable salt thereof, said conopeptide having the general formula V: [Xaa<sub>1</sub>-Xaa<sub>2</sub>-Cys-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Phe-Xaa<sub>5</sub>-Cys-Thr-Xaa<sub>6</sub>-Ser-Xaa<sub>7</sub>-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Gln-Thr-Tyr-Cys-Xaa<sub>8</sub>-Leu-Xaa<sub>9</sub> (SEQ ID NO:5), wherein Xaa<sub>1</sub> is des-Xaa<sub>1</sub> or a dipeptide; Xaa<sub>2</sub> is Asp, Glu or γ-carboxyglutamic acid (γ-Glu); Xaa<sub>3</sub> is a dipeptide; Xaa<sub>4</sub> is Trp or 6-bromo-Trp; Xaa<sub>5</sub> is a dipeptide; Xaa<sub>6</sub> is a dipeptide; Xaa<sub>7</sub> is Glu or γ-Glu; Xaa<sub>8</sub> is any amino acid; and, Xaa<sub>9</sub> is a pentapeptide] ~~Xaa<sub>1</sub>-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Cys-Xaa<sub>3</sub>-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Phe-Xaa<sub>3</sub>-Xaa<sub>3</sub>-Cys-Thr-Xaa<sub>3</sub>-Xaa<sub>3</sub>-Ser-Xaa<sub>3</sub>-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Gln-Thr-Tyr-Cys-Xaa<sub>3</sub>-Leu-Xaa<sub>3</sub>-Xaa<sub>3</sub>-Xaa<sub>3</sub>-Xaa<sub>3</sub>~~ (SEQ ID NO:5), wherein Xaa<sub>1</sub> is des-Xaa<sub>1</sub> or any amino acid; Xaa<sub>2</sub> is Asp, Glu or γ-Glu; Xaa<sub>3</sub> is any amino acid; Xaa<sub>4</sub> is Trp or 6-bromo-Trp; and Xaa<sub>5</sub> is Glu or γ-Glu. --